Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.24 -7.1%	$1.64	$1.22 ▼ $5.38	$119.41M	1.51	625,065 shs	469,136 shs
GHRS GH Research	$9.86 -5.2%	$11.87	$6.00 ▼ $20.50	$513.00M	0.94	165,710 shs	207,489 shs
INCR InterCure	$1.34 -2.9%	$1.59	$1.17 ▼ $3.72	$60.84M	1.28	36,477 shs	16,738 shs
LVTX LAVA Therapeutics	$1.18 -7.1%	$1.15	$0.85 ▼ $3.57	$31.03M	0.48	169,939 shs	137,147 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-14.51%	-15.05%	-32.25%	-68.38%
GHRS GH Research	-3.35%	-13.76%	+12.92%	+31.48%	-5.80%
INCR InterCure	-0.72%	-5.50%	-15.12%	-12.97%	-48.31%
LVTX LAVA Therapeutics	+1.60%	-0.39%	0.00%	+23.30%	-59.29%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.3029 of 5 stars	3.5	3.0	2.3	0.8	0.6
GHRS GH Research	2.623 of 5 stars	4.5	1.0	2.1	2.5	0.0
INCR InterCure	0.2897 of 5 stars	0.0	4.0	0.0	0.0	0.6
LVTX LAVA Therapeutics	2.4409 of 5 stars	3.0	5.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	527.53% Upside
GHRS GH Research	3.00	Buy	$30.86	212.95% Upside
INCR InterCure	0.00	N/A	N/A	N/A
LVTX LAVA Therapeutics	2.00	Hold	$3.17	168.36% Upside

Current Analyst Ratings Breakdown

Latest ADCT, GHRS, INCR, and LVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
3/31/2025	ADCT ADC Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50
3/13/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
3/7/2025	ADCT ADC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	GHRS GH Research	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$31.00
2/27/2025	GHRS GH Research	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $32.00
2/27/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$2.00 ➝ $1.50
2/24/2025	ADCT ADC Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$6.00 ➝ $8.00
2/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$14.00
1/27/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.72M	1.69	N/A	N/A	($1.93) per share	-0.64
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
INCR InterCure	$272.67M	0.22	N/A	N/A	$2.72 per share	0.49
LVTX LAVA Therapeutics	$7.35M	4.22	N/A	N/A	$1.95 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$240.05M	-$1.65	N/A	N/A	N/A	-300.00%	N/A	-61.33%	5/5/2025 (Estimated)
GHRS GH Research	-$35.59M	-$0.75	N/A	N/A	N/A	N/A	-20.29%	-19.49%	5/2/2025 (Estimated)
INCR InterCure	-$16.83M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/7/2025 (Estimated)
LVTX LAVA Therapeutics	-$41.97M	-$0.93	N/A	N/A	N/A	N/A	-62.22%	-29.37%	5/20/2025 (Estimated)

Latest ADCT, GHRS, INCR, and LVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million
2/27/2025	Q4 2024	GHRS GH Research	-$0.23	-$0.17	+$0.06	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.92	4.68
GHRS GH Research	N/A	15.83	15.83
INCR InterCure	0.15	1.78	1.15
LVTX LAVA Therapeutics	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
GHRS GH Research	56.90%
INCR InterCure	8.34%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	4.10%
GHRS GH Research	41.60%
INCR InterCure	0.24%
LVTX LAVA Therapeutics	0.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	96.69 million	92.73 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
INCR InterCure	350	45.57 million	45.46 million	Optionable
LVTX LAVA Therapeutics	60	26.30 million	26.08 million	Optionable

ADCT, GHRS, INCR, and LVTX Headlines

Recent News About These Companies

LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright

April 1 at 2:29 AM | americanbankingnews.com

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

March 29, 2025 | markets.businessinsider.com

LAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99M

March 28, 2025 | seekingalpha.com

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 28, 2025 | globenewswire.com

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

February 28, 2025 | benzinga.com

Cautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce Reduction

February 27, 2025 | tipranks.com

Lava Therapeutics announces evaluation of strategic options

February 26, 2025 | markets.businessinsider.com

LAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News Summary

February 26, 2025 | benzinga.com

Lava Therapeutics trims workforce by 30% to preserve cash

February 25, 2025 | bizjournals.com

Serina Therapeutics Appoints Karen J. Wilson to Board of Directors

January 14, 2025 | quiverquant.com

LAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood Cancers

January 10, 2025 | quiverquant.com

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

January 10, 2025 | globenewswire.com

LAVA Therapeutics to Transition to U.S. Domestic Issuer

January 2, 2025 | tipranks.com

Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX)

December 13, 2024 | msn.com

JMP Securities downgrades LAVA Therapeutics (LVTX) to a Hold

December 11, 2024 | markets.businessinsider.com

LAVA Therapeutics Reports Increased Losses Amid Declining Revenues

December 10, 2024 | tipranks.com

Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup

December 10, 2024 | fiercebiotech.com

LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs

December 10, 2024 | quiverquant.com

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

December 10, 2024 | globenewswire.com

3 Healthcare Stocks Analysts Expect to Rally Over 50%

September 25, 2024 | stocknews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
4 Healthcare Stocks With Massive Gains—and More to Come
By Sarah Horvath | March 29, 2025
View 4 Healthcare Stocks With Massive Gains—and More to Come
Archer Aviation Stock Sees Surge in Institutional Buys
By Jeffrey Neal Johnson | March 28, 2025
View Archer Aviation Stock Sees Surge in Institutional Buys
Energy Transfer: Powering Data With Dividends and Diversification
By Jeffrey Neal Johnson | March 26, 2025
View Energy Transfer: Powering Data With Dividends and Diversification
AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof Play
By Jeffrey Neal Johnson | March 31, 2025
View AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof Play

ADCT, GHRS, INCR, and LVTX Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.24 -0.10 (-7.14%)

Closing price 03:58 PM Eastern

Extended Trading

$1.24 0.00 (0.00%)

As of 04:26 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

GH Research NASDAQ:GHRS

$9.86 -0.54 (-5.19%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 +0.04 (+0.35%)

As of 04:05 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

InterCure NASDAQ:INCR

$1.34 -0.04 (-2.91%)

Closing price 03:58 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 04:27 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

LAVA Therapeutics NASDAQ:LVTX

$1.18 -0.08 (-6.69%)

As of 04:00 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time